ArticleThe Canadian veterinary journal = La revue veterinaire canadienne2023
Retrospective evaluation of toceranib phosphate (Palladia) use in the treatment of feline pancreatic carcinoma.
Article in The Canadian veterinary journal = La revue veterinaire canadienne, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 4 citations in OpenAlex.
- Oral chemotherapy agents in cats: clinical uses, administration and side effects.Journal of feline medicine and surgery · 2026Review
- Cutaneous paraneoplastic syndromes in cats: a comparative clinical review.Journal of feline medicine and surgery · 2026Review
- Postmortem diagnosis of exocrine pancreatic adenocarcinoma mimicking encapsulating peritoneal sclerosis in a cat: Clinical and histopathological insights.Open veterinary journal · 2025Article
- Pancreatic adenocarcinoma treated with surgical resection, toceranib phosphate and firocoxib in a dog: a case report.Veterinary research communications · 2024Article
- Hyalinizing pancreatic adenocarcinoma in a cat.JFMS open reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To retrospectively assess the biological response in cats with pancreatic carcinoma treated with toceranib phosphate. Animals: Twenty-six client-owned cats. Procedure: Patient information from multiple institutions was solicited Results: Twenty cats were treated for gross disease and 6 for microscopic disease/incomplete margins. Clinical benefit (complete response, partial response, or stable disease ≥ 10 wk) was observed in 9/20 cats treated in the gross disease setting (45%; complete response: Conclusion: Toceranib phosphate was well-tolerated and provided modest clinical benefit to a subset of cats treated. Clinical relevance: Although feline exocrine pancreatic carcinoma continues to be a challenging disease to treat, toceranib phosphate appeared to provide potential clinical benefit.
Indexed as
Identifiers
38046430PMC10637710W4389315610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.